US Senate finance committee asks for Mylan EpiPen rebate investigation

The US Senate Finance Committee on Tuesday said it had asked the US Department of Health and Human Services to investigate the rebates to state Medicaid programs for Mylan Inc's EpiPen treatment.
Mylan, which has raised the US price for a pack of two EpiPens from less than $100 when it acquired the product in 2007 to more than $600, also faces scrutiny from New York Attorney General Eric Schneiderman and West Virginia.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use and privacy policy